Proton beam doses put to the test for tough lung cancers

NCT ID NCT03132532

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tested different doses of proton beam therapy combined with standard chemotherapy for people with stage 2-3 non-small cell lung cancer that cannot be surgically removed. The goal was to find the best radiation dose to control the cancer. Twenty participants received treatment, and researchers tracked how long the cancer stayed under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
proton beam therapy and platinum doublet chemotherapy (carboplatin, cisplatin, paclitaxel, etoposide, pemetrexed)
What this could lead to
If successful, this could help determine the best proton beam dose to improve outcomes for people with inoperable lung cancer.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The optimal dose may not clearly improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.